It reported that patients with normal HER2 protein-expressing tumours (0,1,2 + ) and ISH amplified had no improvement in survival with additional trastuzumab, while patients with IHC 3+ had a significant response to treatment [25]. Here, ERBB2 is linked to neoplasm.